HIV-I Protease Based Inhibitor Discovery by SWAMY, T ANTHONEY & MOSES, GUMMADI SAMUEL
Chemical and Process Engineering Research                                                                                     www.iiste.org 
ISSN 2224-7467 (Paper) ISSN 2225-0913 (Online) 
Vol.7, 2013 
 
1 
 
HIV-I Protease Based Inhibitor Discovery 
Dr. T ANTHONEY SWAMY, M.Sc., M.Phil., Ph.D., I.A.C.T 
Department of Chemistry 
University of Eastern Africa, Baraton, Post Box 2500-30100, Eldoret, Kenya 
Email: drtanthony2011@yahoo.com 
 
Dr. GUMMADI SAMUEL MOSES, M.Sc., Ph. D., PGDEEM., MISTE., FICC., FICS., 
Head, Senior Reader, P.G Dept. of Chemistry 
Government College (NAAC ‘A’ Grade) 
Rajahmundry, Andhra Pradesh 
Email: drgsmoses@yahoo.com 
ABSTRACT: 
We can devise a drug (inhibitor) to restrain the activity of gene. As a gene engenders protein/enzyme, so to 
circumvent the development of any disease causing proteins, we have to stop the activity of that gene. With the aid 
of different bioinformatics tools and software’s we can do this. A protease is an enzyme that smites proteins to their 
constituent peptides. The HIV-I Protease (PR) hydrolyses viral polyproteins into functional protein products that are 
vital for viral assembly and subsequent activity. HIV-I protease activity is decisive for the terminal maturation of 
infectious virions. Once HIV enters the cell, viral RNA experiences reverse transcription to generate double-stranded 
DNA (a step inhibited by nucleoside analogues such as zidovudine, didanosine, zalcitabine, stavudine, and 
lamivudine). 
In the presence of HIV-I protease inhibitors, the virion is incapable to mature and is quickly cleared by inadequately 
comprehended mechanisms. Figure 1, left, is a photomicrograph of normal budding virions from an infected cell, 
while Figure 1, right, determines the effect of bathing these cells with the protease inhibitor, saquinavir. The 
consequent lack of a dense core for these "ghosted" particles is the feature of noninfectious HIV virions. By applying 
ncbi we can acquire the nucleotide and protein sequence of HIV-I Protease. By tool and softwares like pfam, 
clustalw, gold, blast, we designed the inhibitor “SKF 108737”for HIV-I protease. 
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Introduction: 
HIV-I protease (HIV PR) is an aspartic protease that is essential for the lifecycle of HIV, the retrovirus that causes 
AIDS. [1][2] HIV PR cleaves lately synthesized polyproteins at the apposite places to generate the mature protein 
components of an infectious HIV virion. Without effectual HIV PR, HIV virions remain uninfectious.[3][4] Thus, 
mutation of HIV PR’s active site or inhibition of its activity disturbs HIV’s capability to replicate and infect 
additional cells,[5] making HIV PR inhibition the subject of much pharmaceutical research. [6] 
STRUCTURAL FEATURES: 
HIV-I Protease is a homodimer (chain A, chain B). Each monomer consists of 99 amino acids and is alike in 
conformation. The position of each monomer in the ardent protease builds an axis of symmetry. The secondary 
structure of each monomer constitutes, one alpha  helix  and  two  anti-parallel  beta sheets. The two Asp artifacts 
(one from each chain)   function   as   the   catalytic   residues. According to the procedure for HIV PR protein  
cleavage  considered  by  Jaskolski et al., water acts as a nucleophile, which acts in simultaneous conjunction with a 
well-placed  aspartic  acid  to  hydrolyze the scissile peptide bond.[7]  beside, HIV   PR   has the two   molecular   
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“flaps” which  move  a  distance  of  up  to  7  Å when  the  enzyme  becomes  associated with a substrate.[8] 
Aliphatic residues constrain  each  monomer in  a  hydrophobic  core.  in addition,  the dimmer   is   constrained   by   
no   covalent interactions,  hydrophobic  packing  of  side chains    and    interactions    composing    the catalytic 
residues. Each monomer comprises two cysteine residues, but these do not form disulfide bonds. 
The   active   site   forms   at   the   dimmer interface .It is conceived in a cleft between the two  domains as part  of 
four stranded beta turn.  The  substitute  view  ascertains  the position   of   the   active   site   nestled   in 
approximately    in    the    center    of    the molecule. 
An additional turn, a beta hairpin loop, of a beta sheet encases the active site. This flap persists to be adaptable  and  
apportions  for  hinge  like mobility.  It  enables  substrate  access  to  the active site by opening and folding the tips 
into  hydrophobic  pockets  thus  exercising  a central role in protease activity. 
The overall shape of protease is oblong and relatively flat. This surface contour evinces where potential    binding    
or protein   interaction   might   occur:  several binding pockets exist  inside  the  hollow cleft. The structure at left is 
a ligand. 
MECHANISM OF ACTION: 
 
Figure 1: HIV-I Protease 
 
 HIV-I protease activity is captious for the terminal maturation of infectious virions. Once HIV enters the cell, viral 
RNA endures reverse transcription to generate double-stranded DNA (a step inhibited by nucleoside analogues such 
as zidovudine, didanosine, zalcitabine, stavudine, and lamivudine). This viral DNA is incorporated into the host 
genome and, circumstantially, transcribed and translated by cellular enzymes to create large, nonfunctional 
polypeptide chains, insinuated to as polyproteins. After these poly-proteins are comprised and packaged at the cell 
surface, immature virions are generated and released into the plasma. At this point, HIV-I protease, functioning as a 
"molecular scissors," cleaves the poly-proteins into smaller, functional proteins, thereby apportioning the virion to 
mature. In the existence of HIV-I protease inhibitors, the virion is unable to mature and is quickly cleared by 
insufficiently assented mechanisms. 
Figure 1, left, is a photomicrograph of normal budding virions from an infected cell, while Figure 1, right, displays 
the effect of bathing these cells with the protease inhibitor, saquinavir. The consequent lack of a cohesive core for 
these "ghosted" particles is characteristic of noninfectious HIV virions. 
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HIV-I PROTEASE ACTIVE BINDING: 
HIV-I protease consists of two protein chains. The chains are indistinguishable to one another, and each contains 
amino acids. When the two chains amass, a long tunnel is created (as seen from the side view on above left). Protein 
“flaps” envelop the tunnel and open up to allow the enzyme to connect to a protein chain. After connection, the flaps 
then close around the protein chain, thus holding it in the tunnel and allowing the chain to be degraded. 
 
Figure 2:HIV-I protease 
 
The illustration in the center demonstrates the flaps in an open conformation and an inhibitor bound to the active site. 
This is analogous to how a protein chain would be bound during protease activity. When the inhibitor is removed as 
in the illustration on the right, two aspirate residues can be seen (denoted with asterisks), which attack the protein 
chain and do all the work. 
CHEMINFORMATICS: 
The term Chemoinformatics was defined by F.K. Brown [9, 10] in 1998: Chemoinformatics is the mixing of those 
information resources to transform data into information and information into knowledge for the considered assay of 
deriving beneficial decisions faster in the area of drug lead detection and optimization. 
Since then, both spellings have been used, and some have evolved to be ascertained as heminformatics, while 
European Academia settled in 2006 for Chemoinformatics. The current establishment of the Journal of 
Cheminformatics is an energetic push towards the shorter variant. 
Cheminformatics blends the scientific working fields of chemistry and computer science for example in the area of 
chemical graph theory and mining the chemical space.[11, 12] Cheminformatics can also be employed to data 
analysis for distinct industries like paper and pulp,dyes and such allied industries. 
 
COMPUTER AIDED DRUG DISCOVERY: 
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Artificial Intelligence  based drug design supporting systems are employed in this study to identify and in analyzing 
the structure activity data. The understanding of the specificity of the biological function is based on the principles of 
molecular recognition. The binding and action of a drug are controlled by the patterns of molecular fields found in 
the vicinity of the contact surface of the receptor. 
Computational methods employed in this study are on the following patterns. 
1. Structure Based Drug Designing. 
2. Rational (Analogue) Based Drug Designing. 
STRUCTURE BASED DRUG DESIGNING: 
A technique in which 3 dimensional structure of the disease causing molecule is used to design drugs that 
specifically inactivates its function. Structure Based Drug Design is based on a firm understanding of molecular 
recognition between active site groups and interacting molecules and is a strategy that has become an integral part of 
modern drug discovery. 
Latest advances in Structure Based Drug Design methodologies including flexible, faster docking techniques, virtual 
screening and library design. In Structure Based Drug Design, the 3D structure of a drug target interacting with small 
molecules is used to guide drug discovery. “Structure Based Drug Design represents the idea that how molecule 
interacts with its target protein.” Structure Based Drug Design can help lead to better compounds more quickly. 
Structure Based Drug Design is a process whereby the 3D structure of the active site of a biomolecule associated 
with a disease, as well as the relationship between small molecular structures and their bioactivities are studied. To 
design a drug against a specific molecule, the exact structure of that molecule must first be found. 
Using computers we can scan through the PDB and find compounds, which can dock with the active sites and thus 
inhibit the activities of these molecules. Certain computer programs can even design molecules, which fit directly 
into the active sites of the molecules such as enzymes or receptors, thus making very effective inhibitors. 
Materials and Research Methodology: 
PROTEOMICS 
• HIV-I Protease Protein Sequence  
PQITLWQRPLVTIKIGGQLKEALLDTG 
ADDTVLEENSLPGRWKPKMIGGIGGFI 
KVRQYDQILIEICGHKAIGTVLVGPTP 
VNIIGRNLLTQIGCTLNFAAFXFVVX  
ClustalW: Multiple Sequence alignment of HIV-I Protease  
Pfam: Pfam is a large collection of multiple alignments takes HIV-I Protease protein sequences from Swissprot 
database, by using SRS retrieval tool and searches for multiple sequence alignment, against the pfam databases. 
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Similarity structure or sub structure searches:- Searches the similarity structure or sub structure of HIV-I Protease 
inhibitor (SKF 108738) by using NCI-3D search database.  
Draw the HIV-I Protease Inhibitor: 
We have constructed the HIV-I Protease inhibitor 3d structure by using Hyperchem model builder. 
Computational methods for HIV-I Protease Inhibitors (SKF 108738):- 
We are exercising the hyperchem molecular modeling package for computational methods of SKF 108737 
Total energy of molecule: 
Submit the 3D structure of SKF 108737 to Hyperchem tool, and then set up the molecular mechanics force field on 
Hyperchem set up menu. Then click the single point calculations on compute menu of Hyperchem. 
Energy minimizations or Geometry optimizations: 
We have curtailed the energy of SKF 108737 through by altering the geometry and set up the RMS Gradient at 0.01 
in Hyper chem Package. Then click the Geometry Optimization in compute menu of hyper chem. 
Molecular Dynamics Simulations: 
The solvated molecules of SKF 108737 by using periodic boundary conditions in hyper chem. Then exert the 
molecular dynamics in compute menu of hyper chem. 
• Set up the system 
• Starting temperature 100k 
• Resulting temperature 300k 
• Time step 30k 
Monte Carlo Simulations: 
• Applied to the Monte Carlo Simulations. 
• Starting temperature 100k 
• Resulting temperature 300k 
• Time step 30k 
Conformational Analysis: 
We have comported the different conformationals structures of SKF 108738 by using Hyper chem. Molecular 
modeling package.  
Activation energy or Transition state structure: 
We have assessed the transition state of SKF 108738 by using Hyper chem. Molecular modeling package. 
QSAR Studies: 
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We have calculated all the QSAR properties of SKF 108738 by using Hyper chem. Molecular modeling packages. 
 
 
STRUCTURE BASED DRUG DESIGN: 
Structure based drug design is tentative on the existence of a model of the receptor. Many drug receptor interactions 
are administered by a few key receptors groups. The object pf SBDD is to strive and unite with these groups 
collectively to engender conformationally rational, pretentiously target molecules. SBDD experimental part is carted 
out by Ligand Docking (Gold). Taken some chemical compounds (sk-108738, Paraaminobenzoate, Iodopyrazole, 
Guanine) from GenomeNet Database Service (www.genoe.jp/ligand) by using citation from journal of medicinal 
chemistry and protein ligand database. Any peculiar bonds (disulfide bridges etc.) should have CONECT records. 
If a metal ion is existent, affirm that all bonds between the ion and co-coordinating protein or water molecules are 
deleated (GOLD will find them automatically). Metals should be within bonding distance of at least two proteins and 
/or water molecules in the active site so that GOLD can anticipate presumable coordination geometries.   
GOLD: For Docking Set up the GOLD Parameters:- 
 
Figure 4: G.O.L.D. home screen 
General settings  
• External energy weight : 1.37 
• Flood fill probe radius : 1 
• Flood fill point spacing : 0.5 
• Length of H bond : 2.7 
• Maximum Number of operations :100000 
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• Doing simplex minimization after every GA run 
• Angles coded in 8 bits 
• Using ionization dispersion time externally 
• Flattening input amide and trigonal nitrogen’s 
• Solvated point distance : -0.200 
• Number of islands : 6 
• Population size :100 
• Selection pressure :1.2 
• Flood fill radius :10 
• Flood fill origin 
• Cross weight (one string) :90 
• Mutate wt (one string): 90 
• Migration weight : 10 
• Niche size : 2 
Result: MULTIPLE SEQUENCE 
 
Figure 4: 3D STRUCTURE OF SKF 108737 
TOTAL ENERGY OF SKF 108738 BY MOLECULAR MECHANICS: 
Total Energy = 543887.312500 Gradient = 758719.187600 
Molecule Properties:- 
RMS Gradient = 7.577e + 005 k/cal/Amol 
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(Gradient x = 536721.4000 k/cal/Amol, Gradient y = 6134162.5000k/cal/Amol, 
Gradient z = 1013716.000k/cal/Amol) 
Dipole Moment 
Total dipole = 88.85417 Dipole x =87.13437, Dipole y = -11.45754, Dipole z = -13.09165 
ENERGY MINIMIZATION OF SKF 108737:- 
Energy = 83.005364 
Gradient = 0.095556, Converged = yes, Cycles = 962, Points = 2035 
 
Figure 5: MINIMISED ENERGY MODEL 
 
MOLECULAR DYNAMICS SIMULATIONS: 
Time = 1.6ps 
Total Energy = 88.38042 Kcal/mol, T = 283.467K 
At t1=0 
Ekin = 29.2076Kcal/mol, Epot = -66.43Kcal/mol 
EToT = -52.5204 Kcal/mol, T = 99.98592K 
At t2 = 1.6 
Ekin = 13.65412Kcal/mol, Epot = -83.00537Kcal/mol 
ETOT = -53.79776Kcal/mol, T = 46.74193K 
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Figure 6: DYNAMICS MOLECULAR MODEL 
QSAR STUDIES:- 
Surface Area (Appr) = 928.77A 
Surface Area (Grid) = 1000.19 A 
Volume of the Molecule = 1874.72 A 
Log P of the molecule = 2.35 
Hydration Energy = 13.52 Kcal/mol 
Refractivity of Molecule = 171.18A 
Polarisability of Molecule = 70.76 A 
Mass of the Molecule = 653.82 amu 
Active site Analysis SKF 108738:- 
 
LIGAND CHEMISTRY ANALYSIS 
(SKF 108738):- 
Donor atoms: 1 6 11 21 33 40 
No donor atoms 6 
Acceptor atoms: 4 9 21 25 36 43 
DOCKING HIV-1 PROTEASE WITH 
SKF 108738 
Doing GA no population(s) 3 size 100 
selection pressure 1.100000 
Operation Fitness S (hb_ext) S 
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(vdw_ext) S (hb_int) S (vdw_int) 
0 43.91 15.04 53.95 
0.00 -226.51 
497 45.27 12.35 50.35 0.00 - 
177.71 
532 46.09 4.95 49.72 0.00 - 
133.25 
Conclusion: 
BEST DOCKING COMPOUND “SKF 108737” 
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